W
Walking Fish Therapeutics
Rapidly advancing cell-based therapeutics to treat serious diseases, concentrating on oncology and regenerative therapies
About Walking Fish Therapeutics
Walking Fish Therapeutics (WFT) is a biotechnology startup that specializes in B cell engineering. The company has developed a unique platform that leverages the protein production capabilities of B cells to create therapeutics for a range of medical conditions. These include oncology, regenerative medicine, autoimmune disease, and recombinant antibody production.
The company's business model revolves around the production and commercialization of these therapeutic proteins. By engineering B cells to produce specific proteins, Walking Fish can create targeted treatments for various diseases. This includes engineered antibodies for infectious diseases, replacement proteins for deficiency diseases, immune-inhibitory proteins for autoimmune diseases, and regenerative proteins.
Walking Fish operates in the biotechnology market, serving clients in the healthcare sector. These clients can include hospitals, clinics, and other healthcare providers, as well as pharmaceutical companies that may be interested in the company's innovative protein therapies.
The company's revenue is likely generated through the sale of these therapies, as well as through partnerships and collaborations with other entities in the healthcare and pharmaceutical sectors. Walking Fish's business model is supported by a team of cell engineering, manufacturing, and clinical experts, led by repeat entrepreneur and CEO Lewis "Rusty" Williams.
In summary, Walking Fish Therapeutics is a pioneering biotech startup that harnesses the power of B cells to create innovative protein therapies for a range of medical conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- South San Francisco, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 70.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2022 | $73M | $292M | First Spark Ventures · Terra Magnum Capital Partners · Northpond Ventures | ↗ |
| SERIES AOther financing | Sep 2021 | $50M | $200M | Emerson Collective · Quan Capital · Quan Capital · Illumina Ventures | — |
Growth signals
Latest recorded traffic for Walking Fish Therapeutics is 90 monthly website visits, down 94% over the last three months. Walking Fish Therapeutics's team declined 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Walking Fish Therapeutics in the South San Francisco ecosystem
The Walking Fish Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Emerson Collective
Quan Capital
Illumina Ventures
First Spark Ventures
Northpond Ventures- TPTerra Magnum Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Walking Fish Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Walking Fish Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










